Intratumoral CD8+ T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity

Cancer Immunology Research

Volumn 6, Issue 1, 2018, Pages 14-24

  Horton, Brendan L ^a   Williams, Jason B ^a   Cabanov, Alexandra ^a   Spranger, Stefani ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 1BB MAB; CD8 ANTIGEN; MONOCLONAL ANTIBODY; PALLADIUM; PROTEIN BCL XL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; MOUSE; NEOPLASM; NONHUMAN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE EXACERBATION; DISEASE MODEL; DNA DAMAGE; EXPERIMENTAL MELANOMA; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; APOPTOSIS; BIOMARKERS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA DAMAGE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NEOPLASMS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 9;

EID: 85040356563     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-17-0249     Document Type: Article

References (31)

1. Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA 2016;113:E7759-68.
2. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306.
3. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
4. Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med 2017;214:381-400.
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 2012;366:2443-54.
6. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med 2015;373:23-34.
7. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 (+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014;2:3.
8. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
9. Kline J, Brown IE, Zha YY, Blank C, Strickler J, Wouters H, et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008;14:3156-67.
10. Udaka K, Wiesmuller KH, Kienle S, Jung G, Walden P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol 1996;157:670-8.
11. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
12. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002;17:737-47.
13. Martin SJ, Amarante-Mendes GP, Shi L, Chuang TH, Casiano CA, O'Brien GA, et al. The cytotoxic cell protease granzyme B initiates apoptosisina cell-free system by proteolytic processing and activation of the ICE/CED-3 family protease, CPP32, via a novel two-step mechanism. EMBO J 1996;15:2407-16.
14. Garrod KR, Moreau HD, Garcia Z, Lemaitre F, Bouvier I, Albert ML, et al. Dissecting T cell contraction IN VIVO using a genetically encoded reporter of apoptosis. Cell Rep 2012;2:1438-47.
15. Barnes SE, Wang Y, Chen L, Molinero LL, Gajewski TF, Evaristo C, et al. T cell-NF-kappaB activation is required for tumor control in vivo. J Immunother Cancer 2015;3:1.
16. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014;41:830-42.
17. Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest 2013;123:1999-2010.
18. Martinez-Forero I, Azpilikueta A, Bolanos-Mateo E, Nistal-Villan E, Palazon A, Teijeira A, et al. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J Immunol 2013;190:6694-706.
19. Boldajipour B, Nelson A, Krummel MF. Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine. JCI Insight 2016;1:e89289.
20. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest 2016;126:3447-52.
21. Kondoh M, Ohga N, Akiyama K, Hida Y, Maishi N, Towfik AM, et al. Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment. PLoS One 2013;8:e80349.
22. Klein TJ, Glazer PM. The tumor microenvironment and DNA repair. Semin Rad Oncol 2010;20:282-7.
23. Banerjee A, Thyagarajan K, Chatterjee S, Chakraborty P, Kesarwani P, Soloshchenko M, et al. Lack of p53 augments antitumor functions in cytolytic T cells. Cancer Res 2016;76:5229-40.
24. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 2017;355:1428-33.
25. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 2017;355:1423-27.
26. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 2014;211:715-25.
27. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011;34: 236-50.
28. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999;162:5037-40.
29. Weigelin B, Bolanos E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, et al. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci USA 2015;112:7551-6.
30. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015;21:581-90.
31. Evaristo C, Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, et al. Cutting edge: engineering active IKKbeta in T cells drives tumor rejection. J Immunol 2016;196:2933-8.